Both ultimately raise endogenous growth hormone and IGF-1 levels, placing them mechanistically closer to Tesamorelin than to AOD-9604, which was specifically designed to avoid GH/IGF-1 involvement altogether
While caloric restriction alone often results in loss of both fat and muscle, AOD-9604 preferentially targets adipose tissue
Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice
Administration and Safety TB-500 Administration: Commonly given via subcutaneous injection Typically used in 46 week cycles Initial phase: 23 injections per week Maintenance phase: Reduced frequency as directed by a healthcare provider BPC-157 Administration: Can be taken via subcutaneous injection, localized injection, or oral capsule (for gut health) Dosage varies depending on injury type and severity Can be used for short-term injury recovery or longer cycles for chronic conditions Safety Note: Both TB-500 and BPC-157 should be used under medical supervision
Because different pharmacies may use different concentrations, the same 2.5 mg dose may require a different number of units depending on the vial strength
Injection burden 12 injections most days Best for Independent dose control Cycle driver Compound-specific phasing BPC-157 Loading 250500 mcg, daily Frequency Daily Maintenance 250 mcg, daily Route SubQ TB-500 Loading 2.05.0 mg, 2x/week Frequency 2x/week (loading), 12x/week (maintenance) Maintenance 2.0 mg, 12x/week Route SubQ Example Weekly Schedule (Loading Phase) Monday BPC-157 500 mcg SubQ + TB-500 2.5 mg SubQ Tuesday BPC-157 500 mcg SubQ Wednesday BPC-157 500 mcg SubQ Thursday BPC-157 500 mcg SubQ + TB-500 2.5 mg SubQ Friday BPC-157 500 mcg SubQ Saturday BPC-157 500 mcg SubQ Sunday BPC-157 500 mcg SubQ Use separate sterile syringes for separate-vial draws